Autopsy report · NCT00458042

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

“Low Enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 10 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

United Therapeutics

Sponsor type

Industry

Conditions

Hypertension, Pulmonary

Interventions

treprostinil sodium

Participants

10 (planned, not actual)

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.